Illumina, Inc. $ILMN Stock Sold by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 75.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,700 shares of the life sciences company’s stock after selling 35,984 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Illumina were worth $3,202,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ILMN. BlackRock Inc. acquired a new position in Illumina in the 2nd quarter valued at about $3,374,423,000. Primecap Management Co. CA acquired a new stake in Illumina during the 2nd quarter worth approximately $617,981,000. Jupiter Topco LLC acquired a new stake in Illumina during the 2nd quarter worth approximately $358,652,000. Bank of New York Mellon Corp acquired a new stake in Illumina during the 2nd quarter worth approximately $293,846,000. Finally, Bank of America Corp DE purchased a new position in shares of Illumina in the 2nd quarter valued at approximately $255,883,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Key Headlines Impacting Illumina

Investors following ILMN have been watching these headlines:

  • Positive Sentiment: Illumina’s BioInsight AI Lab won the 2026 Virtual Cell Challenge using its Billion Cell Atlas and CellularAI algorithm. The result showcases the company’s AI and genomic-data capabilities, though the announcement does not specify near-term revenue impact. Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
  • Positive Sentiment: A proposed federal bill would require Medicaid coverage for whole-genome and whole-exome sequencing for certain children. If enacted, broader coverage could support more genetic testing and demand for Illumina’s sequencing systems; the bill is not yet law. Genomic Answers for Children’s Health Act of 2026
  • Neutral Sentiment: Recent coverage attributes Illumina’s strong year-over-year performance to clinical sequencing demand, NovaSeq X adoption, and expansion into multiomics and AI. These longer-term drivers may support investor sentiment, but are not a new quarterly update. What’s Fueling Illumina’s Rally?

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $200.65 on Friday. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The company has a market cap of $30.34 billion, a P/E ratio of 34.54, a PEG ratio of 2.85 and a beta of 1.46. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35. The company has a 50-day moving average price of $248.54 and a 200 day moving average price of $180.77.

Illumina (NASDAQ:ILMN – Get Free Report) last released its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter in the previous year, the firm posted $1.34 EPS. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. Research analysts predict that Illumina, Inc. will post 5.43 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ILMN shares. Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Barclays upped their price target on Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research note on Wednesday, October 7th. Weiss Ratings lowered shares of Illumina from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday. Stephens lowered shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective on the stock. in a research report on Friday, October 23rd. Finally, Royal Bank Of Canada boosted their price objective on shares of Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Nine analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $243.72.

View Our Latest Stock Analysis on Illumina

Insider Activity at Illumina

In other Illumina news, Director Keith A. Meister sold 98,833 shares of the stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total value of $21,433,912.71. Following the completion of the transaction, the director owned 208,826 shares in the company, valued at approximately $45,288,094.62. This represents a 32.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Scott D. Ericksen sold 267 shares of the stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $217.76, for a total value of $58,141.92. Following the completion of the transaction, the chief accounting officer owned 14,029 shares of the company’s stock, valued at $3,054,955.04. The trade was a 1.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,201,292 shares of company stock valued at $270,151,290 over the last three months. Insiders own 2.90% of the company’s stock.

Illumina Profile

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Read More

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.